CET and skills guides

Study and gain CET points through OT’s online CET exams, and access archived CET, CPD articles and skills guides in our education library

Find out more

Science and vision

News and features about the latest scientific developments and advances in optometry, ophthalmology and eye medicine

Find out more

Professional support

News and features about the latest developments relating to professional support from across optics. This includes updates from optical organisations such as the AOP and the GOC

Find out more

In practice

News and in-depth features about business management and career development in optics

Find out more


Explore the latest UK and global jobs in the optical sector for optometrists, dispensing opticians and more

Find out more

Eye medicine spending to top 23 billion by 2020

Ophthalmic drugs remain the preferred approach to treat common eye disorders, from dry eye syndrome to glaucoma and AMD, forecast suggests

Ophthalmic drugs

A report predicting trends in the ophthalmic drugs market suggests the global market for medicine to treat eye disease will surpass £23 bn by 2020.

A summary of The Ophthalmic Drugs Market: 2017–2030, published by SNS research, states that although surgery is the only option for the treatment of some eye conditions, including cataracts, ophthalmic drugs continue to account for the highest percentage of spending within the wider market for ophthalmic products.

“As a higher percentage of the global population lives longer, age related eye disorders such as glaucoma, diabetic retinopathy, cataracts and macular degeneration are on the rise,” the summary explains.

“In addition, a host of modern lifestyle habits such as poor eating, overworking and the excessive use of visual displays, have created an environment rife with conditions such as dry eye syndrome and myopia.”

The report summary states that new research and development programmes are primarily focused on anti-inflammatory agents, long-acting anti-VEGF treatments, rho kinase inhibitors, adenosine agonists, nitric oxide donors, combination therapies, complement factor inhibitors and cell therapies, among other areas.

Drug developers are also investing in the development of convenient and potentially cost-effective delivery routes, including oral delivery, intravitreal implants and dissolvable intracanalicular depots.